Clinical trial
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
NCT00005012 · Schering-Plough, Industry · Completed
Key facts
| NCT number | NCT00005012 |
|---|---|
| Title | Safety and Effectiveness of PEG-Intron in HIV-Infected Patients |
| Official title | Antiviral Activity and Tolerability of PEG-Intron in HIV-Infected Subjects Failing HAART |
| Lead sponsor | Schering-Plough, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2b |
| Enrollment | 250 |
| Start date | Mar 1, 2000 |
| Completion | Sep 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: